Canadian Medical Association

2018

Cannabis Opioids

December 4, 2018

CMA response: Health Canada consultation on Canadian drugs and substances strategy

The CMA supports a public health approach to substance use issues, and a comprehensive national strategy to address the harms associated with psychoactive drugs.
Opioids

August 30, 2018

Open letter to Premier Doug Ford and Health Minister Christine Elliott

CMA signs an open letter reinforcing the need to provide greater and more equitable access to supervised consumption sites i…
Opioids

August 14, 2018

CMA response: Consultation on Regulatory Amendments regarding Tramadol

To protect Canadians’ health and safety, the CMA advises tramadol be placed on Schedule 1 of the Controlled Drugs and Substances Act
Opioids

July 18, 2018

CMA response: Consultation on Restriction of Marketing and Advertising of Opioids

The CMA supports Health Canada’s efforts to restrict the ability of drug manufacturers to advertise opioids to health care practitioners

2017

Opioids

November 7, 2017

CMA submission on Non-Prescription Availability of Low-Dose Codeine Products

In the interest of promoting public health and patient safety, the CMA endorses the requirement that all products containing low-dose codeine be sold by prescription only
Opioids

August 22, 2017

Opioids Session on Periscope

At CMA’s 150th General Council in Quebec City, experts discuss the opioid crisis in Canada as part of a Facing Ca…
Opioids

April 6, 2017

CMA submission on the study of Bill C-37: An Act to amend the Controlled Drugs and Substances Act

The CMA makes recommendations to the Senate Committee on Legal and Constitutional Affairs about Bill C-37, An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts

2016

Opioids

October 18, 2016

CMA statement to the House of Commons Standing Committee on Health

Dr. Jeff Blackmer, CMA Vice-president of Medical Professionalism, speaks before the House of Commons Standing Committee on Health about Canada’s escalating public health crisis related to problematic opioid and fentanyl use
Opioids

March 19, 2016

CMA response: Consultation on the Prescription Drug List: Naloxone

In response to Health Canada’s consultation on the prescription drug list, the CMA advocates for increased access to naloxone for emergency treatment of opioid overdose outside hospitals

2015

Opioids

May 30, 2015

Harms Associated with Opioids and other Psychoactive Prescription Drugs

A CMA policy offers background on the harms associated with opioids and other psychoactive prescription drugs subject and ou…
Opioids

May 14, 2015

CMA submission to the Senate Standing Committee on Legal and Constitutional Affairs on Bill C-2: An Act to Amend the Controlled Drugs and Substances Act

The CMA presents its concerns with Bill C-2 before the Senate Standing Committee on Legal and Constitutional Affairs, including that the new legislation could make it harder to create new supervised consumption sites

2014

Opioids

October 28, 2014

CMA submission to the House of Commons Standing Committee on Public Safety and National Security on Bill C-2: An Act to Amend the Controlled Drugs and Substances Act

Concerns about the potential of Bill C-2 impede the creation of new supervised consumption sites feature in the CMA’s submission to the House of Commons Standing Committee on Public Safety and National Security
Opioids

August 26, 2014

CMA response on Tamper Resistance under the Controlled Drugs and Substances Act

The CMA advocates for regulations requiring products containing certain controlled substances to be tamper-resistant as a condition for sale in Canada
Opioids

March 26, 2014

CMA submission on the Senate study on prescription pharmaceuticals

In support of the Senate Committee on Social Affairs, Science and Technology study on prescription pharmaceuticals in Canada, the CMA recommends ways for the federal government to address the unintended consequences of prescription pharmaceuticals and support public health, quality care and patient safety
Opioids

March 17, 2014

CMA submission on the Review of Controlled Drugs and Substances Act

The CMA’s response to Health Canada’s consultation on the Controlled Drugs and Substances Act and its regulations recommends new measures and mechanisms for improving public health and safety, including enhancements to controlled substance approval, labelling and safety monitoring

2013

Opioids

November 27, 2013

The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada

The CMA supports the House of Commons Standing Committee on Health study on the government’s role in addressing prescription drug abuse in Canada with background on the issue and recommendations for tackling the issue, including national strategies for reducing misuse and promoting optimal prescribing